USD
+$0.00
(+0.00%
)At Close (As of Dec 9, 2025)
$3.10B
Market Cap
-
P/E Ratio
-0.65
EPS
$21.73
52 Week High
$5.28
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Total Assets | $352M |
| Total Current Assets | $320M |
| Cash And Cash Equivalents At Carrying Value | $302M |
| Cash And Short Term Investments | $302M |
| Inventory | - |
| Current Net Receivables | $1.4M |
| Total Non Current Assets | $32M |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | - |
| Intangible Assets Excluding Goodwill | - |
| Goodwill | - |
| Investments | - |
| Long Term Investments | - |
| Short Term Investments | - |
| Other Current Assets | $17M |
| Other Non Current Assets | - |
| Total Liabilities | $143M |
| Total Current Liabilities | $111M |
| Current Accounts Payable | $16M |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $7.6M |
| Total Non Current Liabilities | $32M |
| Capital Lease Obligations | $25M |
| Long Term Debt | - |
| Current Long Term Debt | - |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $25M |
| Other Current Liabilities | $21M |
| Other Non Current Liabilities | - |
| Total Shareholder Equity | $210M |
| Treasury Stock | - |
| Retained Earnings | -$1.1B |
| Common Stock | $1.2B |
| Common Stock Shares Outstanding | $138M |
| Field | Value (USD) |
|---|---|
| Operating Cashflow | -$151M |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $8.7M |
| Capital Expenditures | $938K |
| Change In Receivables | - |
| Change In Inventory | - |
| Profit Loss | - |
| Cashflow From Investment | -$938K |
| Cashflow From Financing | $254M |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | - |
| Dividend Payout Common Stock | - |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | - |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | -$97M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Wave Life Sciences Ltd. is a pioneering clinical-stage biotechnology firm based in Singapore, dedicated to developing cutting-edge oligonucleotide therapeutics for severe genetic disorders. Leveraging its proprietary PRISM platform, the company creates stereopure oligonucleotides that significantly enhance the specificity and efficacy of genetic interventions. With a strong pipeline of innovative therapies aimed at addressing critical unmet medical needs, Wave Life Sciences is positioned as a transformative leader in genetic medicine, striving to improve patient outcomes around the world.